ENTA ENANTA PHARMACEUTICALS INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$11.28

Period return

-2.90 (-20.45%)

Volume

135.1K

2026-06-05O $11.68 H $11.68 L $11.25 C $11.28MA5 $11.79MA20 $13.36MA60 $13.44MA120 $13.74

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 02. 10.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 09.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 11. 14.MediumBUY7 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $20.14 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Watertown, MA, United States
Fiscal year end: —
Employees: 120
IPO date: —

2025. 09. 30.LowBUY8 months ago

WestPark Capital: Buy